Skip to content
Companies

Antlia Bioscience

Long-acting peptide therapy for chronic heart failure

Raised to date

$6M

of $20M offered across 1 Form D filing

Still open
$14M
Investors
3
Last filed
Jun 5, 2026

About

Antlia Bioscience is a preclinical biotechnology company in Encinitas, California developing novel long-acting therapeutics for chronic cardiometabolic diseases. Its approach centers on peptide-based therapies for cardiovascular and metabolic conditions, extended in half-life so they can be dosed practically. In 2020 it announced a strategic alliance with XL-protein GmbH to apply that company's PASylation half-life-extension technology to a long-acting peptide treatment for chronic heart failure. The company was incorporated in 2020 and remains a small, privately held research-stage organization.

It pairs cardiometabolic peptide candidates with PASylation, a biological half-life-extension chemistry that slows renal clearance by 10-100x without the immunogenicity concerns of PEGylation, aiming to make otherwise short-lived peptides viable chronic therapies.

Funding

  • EquityFiled Jun 5, 2026Form D
    $6M/ $20M

Product

PASylated long-acting peptide program for chronic heart failure

Preclinical therapeutic program

A preclinical therapeutic program applying XL-protein's PASylation technology to a cardiovascular peptide, extending its plasma half-life so it can be developed as a chronic treatment for heart failure.

  • Peptide therapeutic targeting chronic heart failure
  • PASylation half-life extension using proline/alanine/serine polypeptide fusion
  • Reported 10-100x reduction in renal clearance versus the unmodified peptide

Built for

Patients with chronic cardiometabolic disease, initially chronic heart failure, reached through prescribing cardiologists and, at this stage, biopharma development and licensing partners

People on file